10X Genomics Inc (TXG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 10X Genomics Inc (TXG) has a cash flow conversion efficiency ratio of 0.055x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($43.21 Million) by net assets ($786.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review TXG FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
10X Genomics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how 10X Genomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see 10X Genomics Inc market capitalisation for the company's overall valuation and market capitalisation.
10X Genomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 10X Genomics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
0.055x |
|
Hanwha Life
KO:088350
|
0.068x |
|
Shenzhen China Micro Semicon Co. Ltd. A
SHG:688380
|
N/A |
|
Kingclean Electric Co Ltd
SHG:603355
|
0.040x |
|
Ningbo Jifeng Auto Parts Co
SHG:603997
|
0.112x |
|
Netcompany Group A/S
CO:NETC
|
0.024x |
|
HawkEye 360, Inc.
NYSE:HAWK
|
N/A |
|
Shenzhen Everbest Machinery Indus
SHE:002980
|
0.001x |
Annual Cash Flow Conversion Efficiency for 10X Genomics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of 10X Genomics Inc from 2017 to 2024. View TXG stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $710.13 Million | $6.66 Million | 0.009x | +145.76% |
| 2023-12-31 | $741.04 Million | $-15.20 Million | -0.021x | +50.83% |
| 2022-12-31 | $805.74 Million | $-33.61 Million | -0.042x | -59.54% |
| 2021-12-31 | $817.57 Million | $-21.37 Million | -0.026x | +91.13% |
| 2020-12-31 | $739.07 Million | $-217.90 Million | -0.295x | -457.67% |
| 2019-12-31 | $420.08 Million | $34.63 Million | 0.082x | -76.27% |
| 2018-12-31 | $-219.99 Million | $-76.41 Million | 0.347x | +265.25% |
| 2017-12-31 | $-112.51 Million | $-10.70 Million | 0.095x | -- |
About 10X Genomics Inc
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and … Read more